Back to top
more

ConforMIS, Inc. (CFMS)

(Delayed Data from NSDQ)

$2.66 USD

2.66
1,165,738

+0.22 (9.02%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -34.85% and 2.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of -5.16% and 2.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

by Zacks Equity Research

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine Holdings (SPNE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

SeaSpine (SPNE) delivered earnings and revenue surprises of -28.57% and 3.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Synchrony Financial (SYF) Ties Up to Ease Orthopedic Care

by Zacks Equity Research

Synchrony Financial (SYF) joins forces with Conformis, which leads to the integration of CFMS' program within SYF's CareCredit solution for offering convenient financing options to orthopedic patients.

New Strong Sell Stocks for February 14th

by Zacks Equity Research

CFMS, JD, and PZG have been added to the Zacks Rank #5 (Strong Sell) List on February 14, 2022

Smith+Nephew (SNN) to Acquire Orlando-Based Engage Surgical

by Zacks Equity Research

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 1.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.

Conformis (CFMS) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Conformis (CFMS) has been struggling lately, but the selling pressure may be coming to an end soon.

Top Ranked Momentum Stocks to Buy for September 22nd

by Zacks Equity Research

CROX, GSKY, RRC, and CFMS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 22, 2021

ConforMIS (CFMS) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 162.50% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and -0.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will ConforMIS (CFMS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

by Debanjana Dey

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Walgreens (WBA) Inks Deal to Expand COVID-19 Testing Access

by Zacks Equity Research

Walgreens' (WBA) recent deal with Abbott is part of its ongoing efforts to offer greater testing access, helping reduce the spread of COVID-19 and improve the health of communities.

Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout

by Zacks Equity Research

Thermo Fisher's (TMO) $17.4-billion acquisition deal will offer the company meaningful cost and revenue synergies.